Merck KGaA starts production of diabetes drug in Russia

27 January 2016

German life sciences and pharma company Merck KGaA (MRK: DE) has officially launched production of its drugs for the treatment of diabetes at the facilities of its Russian partner Nanolek in the Kirov region.

Under the terms of the agreement, the partners plans to focus on the full-cycle production of Glyukofazh (Glucophage; metformin), which is a drug for the treatment of type 2 diabetes.

The annual volume of production will be 400 million tablets, that will allow to fully meet Russia’s needs in the drug.

To date, investments in the project amount to 10 million euros ($10.8 million) and there is a possibility that they will significantly increase during the next several years, as part of Merck’s plans to establish production of drugs for the treatment of hypertension and heart failure in the Kirov region (The Pharma Letter October 22, 2015).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK